Bli medlem
Bli medlem

Du är här


Orexo: OX-MPI project returned to Orexo

Uppsala, Sweden - August 6, 2014 - Orexo AB (publ) announces today
that Boehringer Ingelheim has decided to return the OX-MPI project to
Orexo. The project aims to develop products based on specific
inhibition of prostaglandin E2 (PGE2) in different disease
conditions. Boehringer Ingelheim has since 2005 been responsible for
all research and development within the OX-MPI project.

Orexo is evaluating the results from Boehringer Ingelheim and when
this is completed will make a final decision on the potential to
continue the project with a new external partner. The return of
OX-MPI from Boehringer Ingelheim has no direct impact on the
financial position of Orexo. The OX-MPI project is associated with an
intangible fixed asset of MSEK 62 from the acquisition of Biolipox
and this asset will be impaired if a final decision is taken to
discontinue the project.

For further information, please contact:
Nikolaj Sorensen, President and CEO
Tel: +46 (0)703-50 78 88, E-mail:

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using
proprietary drug delivery technology and commercial operations in the
United States. The company is commercializing its proprietary
product, ZUBSOLV® sublingual tablets, for maintenance treatment of
opioid dependence, in the United States. The ZUBSOLV® sublingual
tablet is a novel formulation of buprenorphine and naloxone using
Orexo's extensive knowledge in sublingual technologies. Orexo has a
portfolio of two approved and revenue generating products currently
marketed under license in the US, EU and Japan. Orexo AB, with its
headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange
and its American Depositary Receipts (ADRs) trade on the OTCQX
marketplace in the U.S. under the symbol, "ORXOY". The largest
shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit

Orexo AB (publ) discloses the information provided herein pursuant to
the Financial Instruments Trading Act and/or the Securities Markets
Act. The information was submitted for publication at 08:30 am CET on
August 6, 2014.


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.